Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence